|
See/download the final announcement!
Hot Topics
Day-at-a-glance:
Saturday Sunday
Monday Tuesday
Wednesday
Outline programme
[PDF]
Abstracts
available here
Invited
speaker abstracts
| Wednesday 28 May, 2008 |
10:00-
11:36 |
 |
HOT TOPICS
Chairs:
Jorge Cannata (Oviedo, Spain)
Richard Eastell (Sheffield, UK) |
|
| 10:00 |
OC36 |
EFFICACY OF DENOSUMAB ON BONE MINERAL DENSITY IN POSTMENOPAUSAL
WOMEN WITH LOW BONE MASS AND PATIENTS WITH BREAST CANCER ON ADJUVANT
AROMATASE INHIBITOR (AI) THERAPY
H. G. Bone*1, G. Ellis2, C. K. Yuen3,
D. L. Kendler4, M. Fan5, H. Wang5,
D. Kim5, Y. Liu5, R. Dansey5, J.
San Martin5
1Michigan Bone and Mineral Clinic,
Detroit, MI, 2Seattle Cancer Care Alliance, Seattle, WA,
United States, 3Univ of Manitoba, Winnipeg, 4Univ
of British Columbia, Vancouver, Canada, 5Amgen Inc., Thousand
Oaks, CA, United States |
|
| 10:12 |
OC37 |
A NOVEL LUNG CANCER SIGNATURE MEDIATES METASTATIC BONE
COLONIZATION BY A DUAL OSTEOLYTIC AND METALLOPROTEOLYTIC MECHANISM
D. Luis-Ravelo*1, S. Vicent1, I. Antón1,
I. García-Tuñón1, S. Martínez1,
C. Zandueta1, J. De Las Rivas2, F. Lecanda1
1Division of Oncology, Center for Applied Medical Research,
Pamplona, 2Bioinformatics and Functional Genomics, Cancer
Research Center, University of Salamanca, Salamanca, Spain |
|
| 10:24 |
OC38 |
GENOME-WIDE ASSOCIATION STUDY IDENTIFIES KLOTHO AND
OTHER NOVEL LOCI AS CONTRIBUTORS TO BMD VARIATION IN POSTMENOPAUSAL
WOMEN
E. L. Duncan*1, F. Rivadeneira2, A. Sims1,
A. Dowling1, T. Doan1, P. P. Arp3,
M. Jhamai3, M. Moorhouse3, D. Evans4,
J. Eisman5, G. Jones6, G. Nicholson7,
R. Prince8, E. Seeman9, J. A. H. Wass10,
A. Hofman11, H. A. Pols2, M. A. Brown1,
A. G. Uitterlinden2
1Musculoskeletal Genetics
Group, Diamantina Institute, University of Queensland, Brisbane, Australia,
2Department of Internal Medicine and Department of Epidemiology
& Biostatistics, 3Department of Internal Medicine,
Erasmus MC, Rotterdam, Netherlands, 4Wellcome Trust Centre
for Human Genetics, University of Oxford, Oxford, United Kingdom,
5Garvan Institute of Medical Research, University of New
South Wales, Sydney, 6Menzies Research Institute, University
of Tasmania, Hobart, 7Department of Clinical and Biomedical
Sciences, University of Melbourne, Geelong, 8School of
Medicine and Pharmacology, University of Western Australia, Perth,
9Departments of Medicine and Endocrinology, Austin Health,
University of Melbourne, Melbourne, Australia, 10Metabolic
Bone Unit, Nuffield Orthopaedic Centre, Oxford, United Kingdom, 11Department
of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, Netherlands
|
|
| 10:36 |
OC39 |
MICRORNAS CONTROL BONE FORMATION IN VIVO AND OSTEOBLAST
DIFFERENTIATION EX VIVO
T. Gaur1, R. Mudhasani1, Z. Li1,
A. J. van Wijnen1, J. L. Stein1, C. M. Croce2,
G. S. Stein1, S. N. Jones1, J. B. Lian*1
1Department of Cell Biology, University of Massachusetts
Medical School, Worcester, 2Department of Molecular Virology,
Immunology, and Medical Genetics and Comprehensive Cancer Center,
Ohio State University, Columbus, United States |
|
| 10:48 |
OC40 |
EXPRESSION OF TRUNCATED ACTIVATOR PROTEIN-1
MEMBERS IN THE HYPOTHALAMUS INCREASES BONE FORMATION
G. C. Rowe*1, H. Saito1, T. Green2,
M. Kveiborg3, E. Nestler2, W. C. Horne1,
R. Baron1
1Oral Medicine, Infection and
Immunity, Harvard School of Dental Medicine, Boston, 2Psychiatry
and Center for Basic Neuroscience, University of Texas Southwestern
Medical Center, Dallas, United States, 3Department of Biomedical
Sciences and Biotech Research & Innovation Center, University
of Copenhagen, Copenhagen, Denmark |
|
| 11:00 |
OC41 |
IMPACT OF BALLOON KYPHOPLASTY ON QUALITY
OF LIFE AND RISK OF RECURRENT VERTEBRAL FRACTURES: A RANDOMIZED TRIAL
IN PATIENTS WITH ACUTE VERTEBRAL COMPRESSION FRACTURES
S. Boonen*1, S. Cummings2, D. Wardlaw3,
R. Eastell4
1Department of Experimental
Medicine, Katholieke Universiteit Leuven, Leuven, Belgium, 2Department
of Experimental Medicine, University of California, San Francisco,
United States, 3Department of Experimental Medicine, Woodend
Hospital, Aberdeen, 4Department of Experimental Medicine,
University of Sheffield, Sheffield, United Kingdom |
|
| 11:12 |
OC42 |
THE TIMING OF DOSING OF ZOLEDRONIC ACID
5MG AFTER RECENT HIP FRACTURE AFFECTS ANTIFRACTURE EFFICACY AND REDUCTION
OF MORTALITY: RESULTS FROM HORIZON-RECURRENT FRACTURE TRIAL
E. F. Eriksen*1, K. W. Lyles2, C. S. Colón-Emeric2,
C. F. Pieper3, J. S. Magaziner4, J. D. Adachi5,
L. Hyldstrup6, C. Recknor7, L. Nordsletten8,
C. Lavecchia9, H. Hu9, S. Boonen10,
P. Mesenbrink9
1Clinical Development and
Medical Affairs, Novartis Pharma AG, Basel, Switzerland, 2Medicine,
3Biostatistics and Bioinformatics, Duke University Medical
Center, Durham, 4Epidemiology, University of Maryland,
Baltimore, United States, 5Medicine, McMaster University,
Hamilton, Canada, 6Endocrinology, Hvidovre Hospital, Hvidovre,
Finland, 7Osteoporosis, United Osteoporosis Centers, Gainesville,
United States, 8Orthapaedics, Ullevål University
Hospital, Oslo, Norway, 9Clinical Development and Medical
Affairs, Novartis Pharmaceuticals Corporation, East Hanover, United
States, 10Geriatrics, Katholieke Universiteit Leuven, Leuven,
Belgium |
|
|
|
|
|
